JNK

下级目录

GSK-2256098
Etalocib
Spisulosine
AS601245
CEP-5214
Pamapimod
SNX-7081
1,9-Pyrazoloanthrone
Miltefosine
HA14-1
Perifosine

目录项下的产品

1224887-10-8
161172-51-6
196497-48-0
345987-15-7
402857-39-0
449811-01-2
449811-01-2 / MFCD49811012
Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor. Pamapimod inhibited p38alpha and p38beta enzymatic activity, with IC(50) values of 0.014 +/- 0.002 and 0.48 +/- 0.04 microM, respectively. There was no activity against p38delta or p38gamma isoforms. When profiled across 350 kinases, pamapimod bound only to four kinases in addition to p38. Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH(2)-terminal kinase (JNK), respectively. Pamapimod inhibited p38 (IC(50), 0.06 microM), but inhibition of JNK was not detected. Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) alpha production by monocytes, interleukin (IL)-1beta production in human whole blood, and spontaneous TNFalpha production by synovial explants from RA patients. Pamapimod is a potent, selective inhibitor of p38alpha with the ability to inhibit the signs and symptoms of RA and other autoimmune
帕吡莫德
908111-22-8
129-56-6
58066-85-6
65673-63-4
157716-52-4